Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) reported late-breaking Phase 2 JASMINE data showing nipocalimab met the primary endpoint in adults with moderate-to-severe systemic lupus erythematosus (SLE).
At 24 weeks, more patients on nipocalimab 15 mg/kg plus background therapy achieved an SRI-4 response than placebo. At 52 weeks, higher SRI-4 and LLDAS rates were maintained, especially in autoantibody-positive patients. The safety profile was consistent with prior studies, with no new safety signals. Nipocalimab has FDA Fast Track Designation in SLE and is being further evaluated in the ongoing Phase 3 GARDENIA study.
Johnson & Johnson (NYSE:JNJ) reported new exploratory biomarker analyses from the Phase 2 DAHLIAS study of nipocalimab in adults with moderate-to-severe Sjögren's disease.
Participants with elevated disease-driving autoantibodies and IgG levels achieved 62.5% response on nipocalimab versus 51.9% overall, supporting ongoing Phase 3 DAFFODIL evaluation. Nipocalimab holds FDA Breakthrough and Fast Track designations for this indication but is not yet approved.
Johnson & Johnson (NYSE: JNJ) reported pivotal Phase 1b/2 OrigAMI-4 data for subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) in previously treated recurrent or metastatic head and neck squamous cell carcinoma.
Confirmed overall response rate was 42%, with 15% complete responses. Median duration of response was not yet reached at 11.8 months. Clinical benefit rate was 63%, median progression-free survival 6.8 months, and overall survival 12.5 months. Safety was mainly Grade 1–2, and an FDA sBLA has been submitted following Breakthrough Therapy Designation.
Johnson & Johnson (NYSE:JNJ) reported final Phase 3 PROTEUS data for investigational perioperative use of ERLEADA (apalutamide) plus hormone therapy in high-risk localized or locally advanced prostate cancer.
The regimen before and after surgery met both primary endpoints, improved multiple disease-control measures, and is not yet approved in this setting.
Johnson & Johnson (NYSE:JNJ) reported updated Phase 1/1b CHRYSALIS-2 data for RYBREVANT plus LAZCLUZE as first-line therapy in atypical EGFR-mutated advanced NSCLC.
Median overall survival reached 41.0 months (~3.5 years), with three- and four-year overall survival rates of 55% and 46%, and a previously reported objective response rate of 57%.
Clinical activity and treatment duration were consistent across multiple atypical EGFR mutation subgroups, and 41% of patients stayed on RYBREVANT for ≥2 years. Safety findings were in line with earlier reports, with mostly Grade 1–2 adverse events and no new safety signals.
Johnson & Johnson (NYSE: JNJ) reported Phase 3 MajesTEC-9 results showing TECVAYLI® (teclistamab-cqyv) improved progression-free survival and overall survival versus standard regimens in relapsed/refractory multiple myeloma after 1–3 prior therapies.
TECVAYLI® cut risk of progression or death by 71% and death by 40%, with 65.9% achieving complete response or better, and has been submitted for regulatory review as early as second-line therapy.
Johnson & Johnson (NYSE: JNJ) received FDA approval for a supplemental Biologics License Application expanding the TREMFYA (guselkumab) label in adults with active psoriatic arthritis.
The label now includes evidence for inhibition of progression of structural joint damage, supported by Phase 3b APEX data showing reduced joint symptoms and structural damage with no new safety signals. TREMFYA is described as the only IL-23 inhibitor with structural inhibition information in its PsA label.
Johnson & Johnson (NYSE: JNJ) will host an investor conference call at 8:30 a.m. ET on Wednesday, July 15 to review second-quarter results, led by CEO Joaquin Duato, CFO Joseph J. Wolk and VP Investor Relations Ryan Koors.
The live webcast, presentation materials and press release (available around 6:45 a.m. ET) can be accessed via www.investor.jnj.com. Telephone dial-in and replay options are provided for U.S. and international participants, with replay access available until 12:00 a.m. on July 29. Investors are also advised of the planned third-quarter earnings call on Tuesday, October 13, 2026.
Johnson & Johnson (NYSE: JNJ) released results from a global survey of 817 non–muscle-invasive bladder cancer patients and 802 urologists across six countries.
Findings show that more than 90% of patients receiving bladder removal or BCG report negative impacts on most life aspects, underscoring the need for treatments reflecting quality-of-life priorities.
Johnson & Johnson (NYSE: JNJ) announced the global launch of the Shockwave C2 Aero Coronary IVL Catheter, a next-generation intravascular lithotripsy device for treating calcified coronary artery disease. The catheter is designed for improved deliverability, lesion crossing and balloon repositioning in complex, tortuous coronary anatomy.
Shockwave C2 Aero maintains Shockwave IVL’s mechanism of action and safety profile, with two emitters delivering up to 240 Shockwaves to fracture hardened calcium while preserving soft tissue. According to Johnson & Johnson, it is now available in the U.S. and Japan, with Europe and Canada to follow.